Service of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, WHO Collaborating Center, Geneva University Hospital, Geneva University, Geneva, Switzerland.
Division of Nephrology, McGill University Health Center, McGill University, Montreal, QC, Canada.
Endocrine. 2023 Aug;81(2):340-348. doi: 10.1007/s12020-023-03400-z. Epub 2023 May 24.
Transsphenoidal surgery for non-functioning pituitary adenomas (NFPAs) can alter pituitary function. We assessed the rates of improvement and deterioration of pituitary function by axis and searched for predictive factors of these outcomes.
We reviewed consecutive medical files from patients having had transsphenoidal surgery for NFPA between 2004 and 2018. Pituitary functions and MRI imaging were analyzed prior and after surgery. The occurrence of recovery and new deficit were documented per axis. Prognostic factors of hormonal recovery and new deficits were searched.
Among 137 patients analyzed, median tumor size of the NFPA was 24.8 mm and 58.4% of patients presented visual impairment. Before surgery, 91 patients (67%) had at least one abnormal pituitary axis (hypogonadism: 62.4%; hypothyroidism: 41%, adrenal insufficiency: 30.8%, growth hormone deficiency: 29.9%; increased prolactin: 50.8%). Following surgery, the recovery rate of pituitary deficiency of one axis or more was 46% and the rate of new pituitary deficiency was 10%. Rates of LH-FSH, TSH, ACTH and GH deficiency recovery were 35.7%, 30.4%, 15.4%, and 45.5% respectively. Rates of new LH-FSH, TSH, ACTH and GH deficiencies were 8.3%, 1.6%, 9.2% and 5.1% respectively. Altogether, 24.6% of patients had a global pituitary function improvement and only 7% had pituitary function worsening after surgery. Male patients and patients with hyperprolactinemia upon diagnosis were more likely to experience pituitary function recovery. No prognostic factors for the risk of new deficiencies were identified.
In a real-life cohort of patients with NFPAs, recovery of hypopituitarism after surgery is more frequent than the occurrence of new deficiencies. Hence, hypopituitarism could be considered a relative indication for surgery in patients with NFPAs.
经蝶窦手术治疗无功能性垂体腺瘤(NFPAs)可能会改变垂体功能。我们评估了各轴系垂体功能改善和恶化的发生率,并寻找这些结果的预测因素。
我们回顾了 2004 年至 2018 年间连续接受经蝶窦手术治疗 NFPAs 的患者的病历。在手术前后分析了垂体功能和 MRI 影像学。记录了每个轴系的恢复和新缺陷的发生情况。搜索了激素恢复和新缺陷的预后因素。
在分析的 137 例患者中,NFPAs 的肿瘤大小中位数为 24.8mm,58.4%的患者存在视力障碍。术前,91 例(67%)至少存在一条异常垂体轴(性腺功能减退:62.4%;甲状腺功能减退:41%,肾上腺皮质功能不全:30.8%,生长激素缺乏:29.9%;催乳素升高:50.8%)。术后,一条或多条垂体轴缺乏恢复的发生率为 46%,新发垂体缺乏的发生率为 10%。LH-FSH、TSH、ACTH 和 GH 缺乏恢复的发生率分别为 35.7%、30.4%、15.4%和 45.5%。新 LH-FSH、TSH、ACTH 和 GH 缺乏的发生率分别为 8.3%、1.6%、9.2%和 5.1%。总的来说,24.6%的患者有整体垂体功能改善,只有 7%的患者术后垂体功能恶化。男性患者和诊断时存在高催乳素血症的患者更有可能经历垂体功能恢复。未发现新缺乏症风险的预测因素。
在 NFPAs 的真实患者队列中,手术后的垂体功能减退症恢复比新缺乏症的发生更为常见。因此,在 NFPAs 患者中,垂体功能减退症可被视为手术的相对适应证。